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Structured summary 56 
Background:  57 
As HIV preventive efforts improve, an increasing population of preadolescent HIV-exposed 58 
but uninfected children face significant developmental and health challenges, including 59 
disclosure of parental HIV. The aim of this research is to test the efficacy of the Amagugu 60 
intervention to increase maternal HIV-disclosure to HIV-uninfected children aged 6-10 years, 61 
leading to improvements in health care engagement and custody planning.  62 
Methods:  63 
Individually randomised efficacy trial in rural KwaZulu-Natal, South Africa; follow-up to 64 
nine months. We used computer-generated simple random sampling with blinded assessment. 65 
The Amagugu intervention included six home-based counselling sessions; the enhanced 66 
standard of care included one clinic-based counselling session. The primary outcome was 67 
maternal HIV-disclosure (full, partial, none) measured at 9-months using an intention to treat 68 
analysis (NIH trial registration: NCT01922882 www.clinicaltrials.gov status: closed). 69 
Findings:  70 
We consecutively approached 634 women at four primary health care clinics (July 2013-71 
December 2014). 464 mothers were randomised (Amagugu intervention n=235; enhanced 72 
standard of care n=229); 428 (92%) completed the 9-month assessment (September 2015).  73 
The Amagugu intervention led to an increase in any disclosure (204/235 vs. 128/229 aOR 74 
9.88 [5.55-17.57] p<0.001) and full disclosure using the words ‘HIV’ (150/235 vs. 98/229 75 
aOR 4.13 [2.80- 6.11] p<0.001). Time to full disclosure was shorter in the intervention group 76 
(median 2.83 vs. ESC median 9.10 months [log-rank test p<0001]).  More mothers in the 77 
intervention group took their child to a clinic visit (aOR 31.49 [17.51-56.61] p<0.001), 78 
discussed a care plan (aOR 3.56 [1.64-7.69] p=0.001), and appointed a guardian (aOR 22.22 79 
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[1.25-3.94] p=0.001). There were no treatment related deaths; but 21 unrelated adverse events 80 
(intervention group=17; enhanced standard of care group=6).  81 
Conclusions and Relevance:  82 
This trial of a psychological intervention, the first from a low-resource setting, demonstrated 83 
positive outcomes. The counsellor-driven intervention changed maternal behaviours 84 
achieving high rates of mother-led HIV disclosure, enhanced health education and custody 85 
planning. Longer term follow-up and effectiveness research is required.    86 
Funding: National Institutes of Health 87 
 88 
 89 
  90 
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Research in context panel 91 
Evidence before this study 92 
Given widespread use of antiretroviral therapy and successful prevention of mother-to-child 93 
transmission, there is a growing population of HIV-negative children living with HIV-94 
infected parents. The literature on parental HIV groups children  by those who are HIV-95 
exposed because their mothers were HIV-infected during their pregnancy resulting in 96 
biological exposure and impacts due to contextual and/or caregiving pathways; and those 97 
who are HIV-affected because their mother has become HIV-infected post birth, so while 98 
biologically unexposed they may still be affected  through contextual/caregiving pathways. 99 
We searched PubMed for English articles published up to 29 April 2017, using the terms 100 
“children” “parental HIV disclosure” “interventions” returning 47 articles. Besides prior 101 
publications on Amagugu, the vast majority focused on interventions for either adolescents or 102 
HIV-infected children, most from high-income settings. Several recent systematic reviews (5 103 
published between 2013-2016) examine outcomes of HIV-infected, HIV-exposed and 104 
affected children, reporting associations between parental HIV, illness or death, and 105 
children’s physical, cognitive, educational, social and emotional outcomes. There is some 106 
evidence that HIV-exposed/affected children may be at increased sexual and abuse 107 
victimisation risk. Reviews confirm benefits of parental disclosure for parents, children and 108 
families, reporting mostly observational research from high-income settings. The absence of 109 
parental disclosure, in particular in the primary school years, can have negative effects. Only 110 
a few qualitative studies report negative effects of disclosure, mostly related to unplanned 111 
disclosures or disclosure as a consequence of parental illness. The World Health Organisation 112 
(2012) guidelines recommend supporting HIV disclosures to exposed/affected children. 113 
Despite documented benefits, disclosure rates remain low, with a systematic review reporting 114 
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disclosure rates from as low as 5% to as high as 67% with a median rate of 41%. Higher rates 115 
of disclosure are noted in older age groups of children. There is a clear need for intervention 116 
studies to address this gap.  117 
Despite Africa bearing the overwhelming burden of HIV across the globe, relatively little 118 
research emanates from the continent. Disclosure rates on the continent suggest that 119 
disclosure often takes place in adolescence, thus missing significant prevention and education 120 
opportunities in earlier childhood. Our search returned a recent systematic review of 121 
disclosure interventions in low and middle-income countries (LMIC) finding only thirteen 122 
studies, twelve of which targeted adults. The Amagugu intervention, reported on here, was 123 
the only disclosure intervention designed to support parental HIV disclosure to primary 124 
school-aged children in LMIC. Two other controlled studies supporting mothers to disclose 125 
to their children were conducted in the United States, targeting adolescents and preadolescent 126 
children. The latter was a pilot trial of the TRACK intervention with 80 families, which 127 
increased disclosure to 33% in the intervention versus 7.3% in the control.  128 
A 2015 commentary on investments made over the last decade by National Institutes of 129 
Health (NIH) in parental HIV disclosure research globally identifies several funded protocols 130 
of controlled studies underway to support parental HIV disclosure. This includes research in 131 
LMIC (predominantly Asia) and one, besides Amagugu, in Africa focused on disclosure to 132 
HIV-infected children in Namibia. We conclude that this is the first randomised controlled 133 
trial to report on a psychological intervention to increase maternal HIV disclosure to HIV-134 
exposed, uninfected preadolescent children in Africa.   135 
Added value of this study 136 
The Amagugu intervention is an established, locally developed conceptual model of a 137 
complex intervention. We demonstrate, for the first time in Africa, that Amagugu 138 
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significantly increases disclosure, parent-child communication about HIV and health, and 139 
promotes custody planning, and that it does not have negative effects for parental or child 140 
mental health.  141 
Implications of all the available evidence 142 
This parent-centred behavioural intervention, delivered by lay counsellors rather than nurses 143 
in a task-shifting model suited to low-resource settings, demonstrates significant success in 144 
changing the behaviour of HIV-infected parents towards disclosure. Given support, and 145 
specific educational guidance, parents are able to engage in HIV disclosure at much higher 146 
rates than previously reported. This efficacy trial finds Amagugu to be acceptable, effective 147 
in producing the intervention targets, and transferable. It has potential for wider scale 148 
implementation following effectiveness research, and may be adapted to other target 149 
populations and other diseases.      150 




Successful Prevention of Mother-to-Child Transmission programmes and HIV treatment 153 
access has changed the HIV landscape dramatically. There are fewer HIV-infected children, 154 
but increasing numbers of children living with HIV-infected parents1 whose HIV can be 155 
successfully managed by antiretroviral treatment (ART).2 These children face 156 
developmental,3 health4 and psychological challenges5 particularly where stigma is high.6 157 
Risks are elevated when mothers become ill or die7 or where there is instability in care8. 158 
Parental HIV may have negative effects on children’s later sexual health, particularly where 159 
children face multiple cumulative risks,9 potentially increasing children’s risk of becoming 160 
HIV-infected.10 The success of HIV programmes needs to be followed by public health 161 
strategies to improve children’s life chances including safeguarding their health, ensuring 162 
ongoing care if their parents become ill, and minimising risks of HIV acquisition. This is 163 
critical as adolescents are the only population in whom  HIV incidence is not decreasing 164 
globally.11   165 
 166 
Parental HIV-disclosure to children offers a good starting point in improving the outcomes of 167 
HIV-exposed uninfected children. The World Health Organisation (WHO) recommends 168 
disclosure to children under 12 years of age.8 Systematic reviews 4,6 consistently conclude 169 
that maternal HIV disclosure to children has benefits for mothers including improved HIV 170 
treatment adherence and compliance, improvements in parent-child and family relationships, 171 
mental health and lower stigma. For children, evidence suggests improvements in custody 172 
and care plans and, in high-income countries (HIC), of mental health improvements. Some 173 
qualitative studies report negative effects, particularly linked to unintended or unplanned 174 
disclosures.12 Importantly, a lack of disclosure has been shown to have negative mental 175 
health impacts for children while for mothers lower disclosure is associated with non-176 
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adherence6. Despite the reported benefits of maternal HIV disclosure,12 rates of parental 177 
disclosure remain low globally8 with few interventions appropriate to low-resource settings.13  178 
Two clinical trials in HIC have tested parental HIV disclosure interventions, one with 179 
adolescents,6 the other with children aged 6-12 years.14 The latter trial (United States) 180 
randomised 80 families to an intervention comprising three home visits, telephone support 181 
and educational materials, finding mothers were almost five-fold more likely to disclose than 182 
controls (33% vs. 7%).  In HIV prevalent settings interventions focused on younger children 183 
are particularly important because household HIV burden is high12 and non-disclosure of HIV 184 
has been shown to  have negative effects.6 A recent systematic review of disclosure 185 
interventions in low-and-middle-income- countries (LMIC)s13 found 13 interventions, 12 of 186 
which focused on adult disclosure to other adults, while only one, the Amagugu intervention 187 
being tested here, focused on children. Prior to this randomised controlled trial we conducted 188 
a pilot study15 and a large scale uncontrolled evaluation including 281 families16,17. Amagugu 189 
is an IsiZulu word which directly translated means “treasures” referencing the importance of 190 
children and families in society.  191 
The primary aim of this study was to test the efficacy of the Amagugu Intervention. Using a  192 
randomised controlled design we hypothesize that when compared to an enhanced standard of 193 
care which provided a once-off counselling session at a Primary Health Care (PHC) facility, 194 
the Amagugu intervention would significantly increase rates of maternal HIV disclosure to 195 
HIV-uninfected children aged 6-10 years, leading to secondary benefits, including 196 
improvements in health care engagement, custody planning and the parent-child relationship.  197 
Methods  198 
Trial Design 199 
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This trial was an individually randomised, efficacy trial, with blind assessment (2013-2015) 200 
with follow-up to nine months post baseline.  201 
Participants 202 
The trial was undertaken at the Africa Health Research Institute (previously known as the 203 
Africa Centre for Population Health) in a rural HIV-endemic region of KwaZulu-Natal, South 204 
Africa, with good HIV treatment coverage.18 Participants were recruited from four PHC 205 
facilities with well-established HIV treatment programmes.  To be eligible, mothers had to 206 
have tested HIV-positive at least 6 months previously; have initiated HIV treatment or be 207 
enrolled in pre-treatment HIV care; have an HIV-uninfected child (aged 6-10 years) resident 208 
in her household; have not disclosed to any children in the household under 10 years of age; 209 
have not participated in the previous Amagugu pilot or evaluation studies; and have mental 210 
capacity to consent. In the first six months, given a slower than expected recruitment rate, the 211 
upper age limit for inclusion of children was increased from nine to 10 years of age, and 212 
recruitment sites were expanded from one to four PHC facilities.  213 
The Amagugu intervention  214 
The Amagugu intervention conceptual framework (Supplementary Figures 1,2)19 draw on 215 
well-established evidence that maternal avoidant coping and a lack of disclosure and 216 
communication can lead to psychological distress in children and increased pressure on the 217 
parenting role. The intervention aims to shift maternal parenting behaviours to an active 218 
coping style, and emphasises behavioural change towards parenting practices which address 219 
important issues linked to the children’s wellbeing, including health education and custody 220 
planning. 221 
The Amagugu intervention included six 1-2 hour sessions delivered to mothers at home, over 222 
an 8-12 week period. It included printed materials and activities supporting age-appropriate 223 
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disclosure, and addressing maternal preparation for children’s emotional reactions and 224 
questions following disclosure.15-17 A detailed description of the intervention and the content 225 
of each of the sessions are included in the supplementary materials (Supplementary Table 2). 226 
While structured, the intervention was flexible allowing mothers to adjust the content to suit 227 
their circumstances and their child’s developmental needs. Mothers selected the level of 228 
disclosure they were comfortable with, either partial (using the word ‘virus’) or full (using 229 
the words ‘HIV’) disclosure. The female lay-counsellors, all high-school graduates with 230 
several years’ counselling experience, did not intervene directly with children but supported 231 
the mother to communicate with her child independently, thus enabling skills transference. 232 
The two-week counsellor training used the Amagugu training materials, including practical 233 
exercises and competency testing. Counsellors were seen fortnightly for supervision and 234 
managed between 15-25 families concurrently.   235 
The enhanced standard of care 236 
There is no standard of care in the South African Department of Health (DOH) regarding 237 
parental HIV disclosure to HIV-uninfected children, beyond a recommendation to 'counsel-238 
to-disclose'. After randomisation, participants in enhanced standard of care were offered a 239 
once-off counselling session, focused on disclosure, delivered at the PHC facility as part of 240 
routine HIV services, either immediately or at another more convenient time. Participants 241 
who deferred counselling were re-approached and reminded about the offer of counselling by 242 
telephone and at their regular clinic visits but no follow up or counselling was conducted 243 
outside the clinic facility, there was no follow up at home. The one hour session provided 244 
information on the benefits of disclosure, disclosure guidance using a short vignette, and 245 
encouraged mothers to bring their children to a clinic visit and undertake custody planning. 246 
Counselling took place in a private furnished room, however, unlike in the Amagugu 247 
intervention no intervention materials were provided. Counsellors delivering the enhanced 248 
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standard of care had equivalent qualifications and experience to those in the intervention arm, 249 
and participated in a one-day training workshop using a training manual, role-plays and 250 
competency testing. They were seen every two months for supervision.  251 
Standardisation of clinic services and intervention fidelity 252 
Clinic staff, including HIV treatment nurses and counsellors, participated in a half-day 253 
workshop on the benefits of HIV disclosure, and health care engagement and custody 254 
planning for HIV-exposed children. 255 
Both the Amagugu intervention and the enhanced standard of care counsellors participated in 256 
case reviews and completed study specific fidelity checklists developed and tested during the 257 
evaluation study.16,17 An experienced trainer (isiZulu-speaking PhD student) conducted 258 
fidelity observations (using study specific scoring sheets) with 10% of participants in both the 259 
Amagugu intervention and enhanced standard of care arms, observing all counsellors across 260 
all intervention sessions. Average fidelity scores were >90% over the trial duration.  261 
The two counselling teams (enhanced standard of care and Amagugu intervention) operated 262 
completely independently of each other. Counsellors were line- managed by different 263 
individuals, used separate transport services, were supervised separately, had differing scopes 264 
work, and were based at different geographical locations.  Case reviews, supervision, and all 265 
aspects of the two arms were operationalized separately, and contact between staff was 266 
minimised.   267 
Outcomes 268 
The primary outcome (disclosure) and some secondary outcomes (health care engagement 269 
and care/custody planning) were measured using study specific surveys (used previously16,17) 270 
at baseline and 3, 6 and 9 month follow-up. For disclosure, if participants reported partial 271 
disclosure at an early time point, the survey was repeated at all further assessments, or until 272 
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full disclosure was reported. No imputation procedure was implemented to deal with lost-to-273 
follow-up in line with an intention-to-treat principle. Other secondary outcomes were 274 
measured using psychometric scales, in interview format, in isiZulu, all of which have been 275 
used previously either in the study population or in other research with similar South African 276 
populations. All measures had good reliability scores in this randomised controlled trial (see 277 
supplementary Table 2 for full description and references).  278 
Maternal mental health: Patient Health Questionnaires Depression (PHQ-9) and Anxiety 279 
scales (GAD-7) at baseline, 3, 6, 9 months.     280 
Health-related quality of life:  Rand Health Medical Outcomes Study Short Form (MOS-36 281 
SF) (General Health subscale) at baseline, 9 months.  282 
Parenting and the parent-child relationship: Parenting Stress Index short form (PSI-36SF) at 283 
baseline, 3, 6, 9 months. 284 
Child mental health: Child Behaviour Checklist (CBCL) at baseline, 6, 9 months. 285 
Family functioning: McMaster Family Assessment Device (FAD) at baseline, 3, 6, 9 months.  286 
Sample size 287 
A sample size of 480 participants followed for 9 months was calculated to achieve 90% 288 
power to detect a difference of 30% versus 45% (probability of type-one error of 5%, two-289 
tailed) amongst women who undertook HIV disclosure to children, allowing for a 20% loss to 290 
follow-up (i.e. final sample of 384 women). 291 
Randomisation 292 
Screening, enrolment, randomisation and data collection used the Mobenzi Mobile 293 
Researcher Platform (MRP) (Mobenzi www.mobenzi.com), previously validated and used in 294 
South Africa.20 Assessments, conducted via mobile phone, were uploaded to the MRP (via 295 
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secure SMS data transfer). Simple random sampling was used. Randomisation was completed 296 
in the MRP with guidance from the trial’s statistician, using a computer generated random 297 
numbers algorithm, to create a pre-randomised list of participant IDs linked to each of the 298 
four PCH facilities. The number of IDs randomised was based on the estimated maximum 299 
recruitment estimates. The interviewer informed the participant of their randomisation to 300 
either home or clinic counselling (Supplementary Figure 3). Participants were allocated to 301 
counsellors electronically (ensuring even distribution); counsellors were notified of their 302 
participant’s contact details via SMS. Outcome measures were collected using follow-up 303 
surveys by independent interviewers, blind to participants’ randomisation and counsellor 304 
allocation. The MRP automated system delivered surveys and contact details of participants 305 
to the interviewers’ mobile phone one week prior to the assessment date. The data collection 306 
protocol allowed the 9 month outcome assessment to be completed for up to 60 days post its 307 
due date, thereafter participants were declared loss to follow up if they could not be traced. 308 
The majority of assessments were completed within 20 days of being due.     309 
Research Ethics approval 310 
Ethical permission was granted by the University of KwaZulu-Natal Biomedical Research 311 
Ethics Committee (BREC) (BFC273/12), and the DOH Provincial Research Ethics 312 
Committee (HRKM078/13).   313 
We established a Data Safety and Monitoring Board (DSMB) prior to recruitment and 314 
undertook four reviews during the trial. The MRP provided an automated weekly report 315 
identifying potential harms using follow-up assessment data, including measures of potential 316 
suicide ideation and adverse effects of disclosure. Serious adverse events were defined by a 317 
Terms of Reference approved by the DSMB and BREC, and reported to the DSMB and 318 
BREC within three, and seven days respectively. They included: maternal or child death, 319 
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illness requiring hospitalisation >5 days, severe psychological/psychiatric illness (including 320 
psychosis, suicide ideation), trauma, violence or stigma as a direct result of the intervention 321 
or control conditions.  322 
Statistical methods  323 
The intention-to-treat principle was followed in the statistical analyses. We compared 324 
continuous variables using independent, two-sample t-tests and Wilcoxon-Mann-Whitney 325 
tests.  Normality and homoscedasticity were assessed using the Shapiro-Wilk and Bartlett’s 326 
tests, respectively. The interquartile range (IQR) was used as a measure of dispersion.  We 327 
fitted logistic and ordinal (proportional odds) regression models adjusting for covariates 328 
where necessary to compare the main outcomes.  Time to disclosure was analysed using 329 
Kaplan-Meier estimates and the log-rank test assessed differences in time to disclosure by 330 
study arm. Mixed-effects models with random effects in the intercept were fitted to account 331 
for the repeated measures resulting from the trial’s protocol. Cox proportional hazard models 332 
were also fitted to analyse outcomes related to time to any and full disclosure.    The 333 
assumption of proportional hazards was evaluated using the Therneau-Grambsch test.21  334 
Statistical analyses were performed using R version 3.2.1 and were undertaken by an 335 
independent trail statistican.  336 
Role of funding source 337 
The funder (National Institutes of Health) had no role in study design, data collection, data 338 
analysis, data interpretation, or writing of the report. The corresponding author had full 339 





We consecutively approached 634 women attending HIV facilities (01 July 2013-01 343 
December 2014); 482 met eligibility criteria: 18 (3.7%) declined participation; 464 mothers 344 
were randomised into enhanced standard of care (n=229) and Amagugu intervention (n=235) 345 
conditions, and 428 (92%) completed the 9-month end-point assessment (31st October 2015) 346 
(Figure 1 Trial Profile).  347 
Non-completion rates of the 9-month assessment were 9.4% (22/235) in the Amagugu 348 
intervention group and 6.1% (14/229) in the enhanced standard of care group; these were not 349 
significantly different (Chi-squared p=0.39).  In the enhanced standard of care arm 96 350 
participants received counselling and 133 did not. Of these, 9, and 5, respectively were not 351 
followed-up to 9 months.  The distribution of lost-to-follow-up in the three groups 352 
(intervention; standard of care treatment compliant; standard of care treatment non-353 
compliant) was not significantly different (Chi-squared p=0.22). 354 
Primary outcomes 355 
As shown in Table 1, at baseline, significant differences between the Amagugu intervention 356 
and enhanced standard of care groups included that the intervention group had a higher 357 
number of boy children; higher levels of maternal employment and there were also 358 
significant differences in child age between the two groups, but the actual difference was 359 
small (median 7.7 vs. 7.9 years).  360 
Adjusting for these three baseline differences, the intervention led to a nine-fold increase (p< 361 
0.001) in any disclosure (including partial or full disclosure) and a four-fold increase 362 
(p<0.001) in full disclosure (using the words ‘HIV’ during disclosure) to children.  These 363 




The intervention led to substantially higher rates of any disclosure (partial or full) in the 366 
intervention arm (204/221 or 92%, missing n=14), as compared to any disclosure in the 367 
standard of care (128/224 or 57%, missing n=5). When examining proportions of full 368 
disclosure only we show similarly higher rates in the intervention (150/221 or 68%) versus 369 
the standard of care group (98/224 or 44%).   370 
 371 
Secondary outcomes 372 
Unadjusted time to any disclosure was significantly shorter in the Amagugu intervention 373 
group (median 2.14 months) vs. enhanced standard of care (median 7.46 months, log rank test 374 
p<0001), as was time to full disclosure (intervention median 2.83 months vs. standard of care 375 
median 9.10 months, log-rank test p<0001) (see Kaplan Meier Curves of both times to 376 
disclosure in supplementary Figure 4). To account for the three covariates significantly 377 
associated with trial arm we fitted multivariable Cox -proportional hazard models to both 378 
times to disclosure; in both models the assumption of proportional hazards was not rejected. 379 
For time to any disclosure the adjusted hazard ratio (aHR) was 0.29 (p<0.001) and only the 380 
child’s gender had a significant effect (aHR=1.25, p=0.047), indicating that participants in 381 
the enhanced standard of care arm had a 29% probability of completing disclosure compared 382 
with the Amagugu intervention arm, and that enhanced standard of care participants were 383 
25% more likely to disclose if disclosure was to a girl child rather than to a boy child.  For 384 
time to full disclosure the aHR between arms was 0.39 (p<0.001), whilst the only covariate 385 
with a significant effect was child age (AHR=1.12, p=0.025).   386 
 387 
Amongst the 403 mothers with other children, we undertook some exploratory analysis into 388 
whether there were inter-arm differences in maternal disclosure to these children:  60/197 389 
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mothers in Amagugu intervention and 44/206 mothers in enhanced standard of care group 390 
disclosed to at least one other child (OR=1.61, p=0.041).   391 
   392 
Compared to enhanced standard of care, many more mothers in Amagugu intervention took 393 
their child to a clinic visit (202/221, 91% versus 63/224, 28% p<0.001, missing n=14), 394 
completed a care plan (182/221, 82% versus 108/224, 48% p<0.001, missing n=5), and 395 
discussed the care plan with the child (Table 2). More mothers in Amagugu intervention 396 
appointed a guardian and did so earlier in the intervention. 397 
 398 
There were no significant differences between the groups in terms of maternal or child mental 399 
health (although both groups showed improvements), or in family functioning, health-related 400 
quality of life, or overall parental stress.  However, compared to the enhanced standard of 401 
care, mothers in the Amagugu intervention had significantly lower scores on the Parent-Child 402 
Dysfunctional Relationship subscale of the PSI-36SF (Table 3, Figure 2).  403 
 404 
Adverse events 405 
There were 17 adverse events reported in the Amagugu intervention: 5 Domestic Violence 406 
(expected/unrelated); 2 participant deaths (expected/unrelated); 2 Participant illness 407 
(requiring hospitalisation >5 days) (expected/unrelated); 3 Family member death 408 
(expected/unrelated); 1 Family illness (expected/unrelated); 4 sexual assault (3 participants 1 409 
other family member) expected/unrelated.  410 
There were 6 adverse events reported in the enhanced standard of care: 1 Domestic Violence 411 
(expected/unrelated); 1 participant death (expected/unrelated); 2 Participant illness (requiring 412 
hospitalisation >5 days) (expected/unrelated); 1 Serious psychiatric illness (participant child) 413 
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(unexpected/unrelated); 1 sexual assault (3 participants 1 other family member) 414 
expected/unrelated.  415 
Discussion 416 
This low-intensity intervention, delivered by lay counsellors, led to substantially increased 417 
rates of maternal HIV disclosure in a relatively short time period, with significant 418 
improvements in healthcare engagement and care planning for the child, and further 419 
disclosures to other children in the home. In the enhanced standard of care arm there were 420 
substantially lower rates of disclosure, health care engagement and care planning. We did not 421 
find significant differences between groups on psychological outcomes, although both groups 422 
showed marked improvements from baseline suggesting that disclosure did not lead to 423 
obvious negative mental health effects, and there was evidence for benefits in the quality of 424 
the parent-child relationship.  425 
These findings are important because, notwithstanding access to lifesaving ART, HIV-426 
infected mothers still face challenges including maintaining lifelong treatment, and 427 
negotiating possible periods of illness and hospitalisations, which impact on family life and 428 
caregiving.7 Stigma is often high,9 leaving parents and children socially isolated and 429 
stressed.4 While parents often avoid disclosure about HIV in an effort to protect children,6,16 430 
by primary school-age children are likely to be aware of parental HIV, particularly in 431 
epidemic areas.12,16,19 Rates of disclosure in the Amagugu intervention were higher than those 432 
recorded in other research across the globe, including in Africa: Uganda (50%); Asia: 433 
Thailand (35%); North America: Canada (31%) and Europe (11%). Likewise, participants 434 
were willing to disclose to children at younger ages than has generally evidenced in LMIC 435 
literature.6  Developmental literature on parents with other life-threating diseases suggest the 436 
absence of communication about parental illness has negative effects on children.22 With 437 
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millions of families affected by HIV in sub-Saharan Africa,1 interventions which improve 438 
family communication and planning23, in the context of HIV,4,7 have important potential 439 
public health benefits.  440 
Improved family communication and increased disclosure to children may hold longer term 441 
benefits for mothers, given evidence that increased maternal disclosure to children is 442 
associated with improved treatment adherence and compliance with clinical appointments.6 443 
That the Amagugu intervention achieved a high level of behavioural change in the mother, 444 
not only in HIV disclosure but also in engagement with a clinic visit and custody planning, in 445 
a short time, is encouraging. There is evidence, from other parenting intervention work in 446 
South Africa, to suggest that if programmes for HIV-infected parents and their children do 447 
not target HIV disclosure directly, disclosure rates remain low, and that this non-disclosure is 448 
associated with increased behavioural problems in children over time.24,25  The primary and 449 
secondary outcomes of this trial suggest that without the benefit of an intervention which 450 
actively encourages parents to deal with communication about HIV, health education and 451 
care planning, the rates of these remain low, which is concerning since the absence of these 452 
are known to confer risks.5,19  453 
We found that enhanced standard of care mothers were more likely to disclose to girls than 454 
boys,6,7 possibly linked to expectations that girls will assist with caregiving during illness. 455 
HIV-infected parents face multiple stressors, including strained family relationships, 456 
complicating care planning for children.26 When HIV disclosure does not occur, or occurs 457 
during periods of maternal illness, children are more likely to have emotional and behavioural 458 
difficulties6 and risk of neglect.27 Timely maternal HIV-disclosure, with planning prior to 459 
illness, may mitigate some of the effects of maternal HIV-related illness on children. Further, 460 
given the evidence of increased sexual and reproductive health risks in this population in 461 
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adolescence, disclosure communication in earlier childhood may also provide opportunities 462 
to begin prevention early.19 463 
A key aspect of the intervention was that primary school-aged children were given the 464 
opportunity to learn about HIV (or a virus), to become familiar with their local health care 465 
clinic, and to have input into their own care plan. The Amagugu model19 (illustrated and 466 
described in supplementary materials) proposes that providing children with age-appropriate 467 
health and disease information22,23 may have prevention effects, improving their ability to 468 
develop healthy practices and prevent longer-term risky behaviours.28,29 We find that 469 
participants in the Amagugu intervention arm reported significant improvements in parent-470 
child interactions.  That Amagugu intervention mothers were more likely to take their child to 471 
clinic is encouraging as children would seldom accompany an adult to clinic in this context 472 
due to financial and time barriers. Early engagement of children in healthcare has 473 
demonstrated benefits both outside of , and in the context of, life threatening parental 474 
illness.22  475 
Another key positive outcome was the increase in custody planning with the Amagugu 476 
intervention group. HIV-infected parents often express concerns about the future care of their 477 
children in the event of their own death.26 Custody planning can decrease the likelihood of 478 
children being moved between households, separated from siblings, or placed in foster 479 
care.5,7 Empirical studies on the adjustment of children orphaned by HIV highlight the 480 
importance of providing a supportive family environment and limiting the number of 481 
household moves during illness, or after a parent’s death.6,7 Therefore, custody planning can 482 
temper the potential detrimental effects of parental illness and possible death on the child.  483 
Strengths and weaknesses 484 
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The limitations of this research include that there was an established HIV treatment 485 
programme in the study area, thus the results may not be generalizable to other parts of Sub-486 
Saharan Africa with poor HIV treatment access. Further, the follow-up period was relatively 487 
short, and longer follow-up may be required to examine longer-term effects, including 488 
benefits for children’s mental health. A potential limitation in the design includes that whilst 489 
every effort was made to ensure that counsellors did not meet or discuss participants, it was 490 
possible that this happened in a small number of cases. Likewise, whilst it was unlikely that 491 
mothers in the two arms met to discuss their counselling, there was a small chance this 492 
happened and may have led to contamination.  493 
Strengths of this research include its focus on children aged 6-10 years who are particularly 494 
under researched in African contexts.  Furthermore the Amagugu intervention specifically 495 
targeted mothers (as opposed to father and other caregivers) for training, a pragmatic decision 496 
since the majority of HIV-exposed children in Africa live with their mothers.1 As reported 497 
elsewhere19 the intervention is highly adaptable, allowing for inclusion of fathers and other 498 
family members in the disclosure process. An additional strength is that the intervention may 499 
be adaptable for other target populations, such as HIV -infected children. Intervention 500 
mothers were able to disclose to their children independently, and to other children in the 501 
household after the intervention, suggesting that skills gained through the intervention are 502 
transferable and effective for disclosure to younger children. While the Amagugu 503 
intervention is low intensity with only 6 sessions, compared to other interventions being 504 
tested with include between 14 and 24 sessions30, it is possible that in future research some 505 




We demonstrate that a low intensity counsellor-driven intervention can change maternal 508 
behaviours towards communicating about HIV, achieving high rates of mother-led disclosure, 509 
enhanced health education, and care planning. Supporting parents to disclose to their 510 
preadolescent children (as recommended by the WHO) showed no evidence of negative 511 
impacts on children, and some evidence of improvements in parent-child relationship.  512 
Globally adolescents are at high risk of HIV, and preventative interventions for that age 513 
group to date have shown little promise. HIV-exposed-uninfected children have heightened 514 
vulnerabilities and this, the first controlled study of a psychological intervention focused on 515 
HIV and targeting these children in LMIC, has demonstrated positive outcomes. It builds on 516 
existing evidence, mostly from HIC settings, which suggests that increased disclosure about 517 
parental life-threating illness, undertaken in a developmentally sensitive manner, improves 518 
parent-child communication about difficult-to-discuss health topics.  519 
Increased communication and education of children about healthy behaviours, including HIV 520 
prevention before behaviours are established, may have potential to improve adolescent 521 
health behaviours among these high risk children as they mature. Longer term follow-up and 522 
effectiveness research is required.    523 
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Table 1 Sample characteristics by group (Amagugu intervention and enhanced standard of care) 
Characteristics 
Total (n = 464) 
Amagugu 
intervention (n = 
235) 
Enhanced standard 
of care (n = 229) 
 n (%) n (%) n (%) p-value 
Maternal age median (IQR)in years 33 (29-39) 32 (29-39) 34 (29-39) 0.633 
Maternal duration of ART median (IQR) in years 2.58 (1.29-4.66) 2.60 (1.29-5.02) 2.50 (1.29-4.33) 0.649 
Maternal education 
    None 25  (5) 18  (8) 7  (3) 0.071 
Some Primary 74  (16) 31  (13) 43  (19) 
 Grade 5 (Primary complete) 102  (22) 47  (20) 55  (24) 
 Some Secondary 143  (31) 78  (33) 65  (28) 
 Grade 12 (Secondary complete) 115  (25) 57  (24) 58  (25) 
 Tertiary 5  (1) 4  (2) 1  (<1) 
 Maternal employment 
    Yes 111  (24) 67 (29) 44 (19) 0.022 
No 353 (76) 168 (71) 185 (80) 
 Maternal HIV treatment 
    Yes 416 (90) 207 (88) 209 (91) 0.367 
No 49 (10) 28 (12) 21 (9) 
 Maternal health perceptions (MOS) 
    Excellent 87 (19) 47 (20) 40 (17) 0.726 
Very good 150 (32) 75 (32) 75 (33) 
 Good 134 (29) 63 (27) 71 (31) 
 Fair 74 16) 41 (17) 33 (14) 
 Poor 20 (4) 9 (4) 11 (5) 
 Maternal relationship status 
    Not in a relationship 63 (13) 34 (14) 29 (13) 0.612 




In relationship with new partner 216 (47) 112 (48) 104 (45) 
 Mother living with partner 
    Yes 132 (28) 63 (27) 69 (30) 0.595 
No 270 (58) 138 (59) 132 (57) 
 Not in relationship (n/a) 63 (14) 34 (14) 29 (13) 
 Mother knows partner HIV status  
   Yes 151 (33) 78 (33) 73 (32) 0.903 
No 119 (26) 60 (26) 59 (26) 
 Not applicable 195 (42) 97 (41) 98 (42) 
 Mother's partner's HIV status 
    Positive 117 (25) 64 (27) 53 (23) 0.444 
Negative 31 (7) 13 (6) 18 (8) 
 Indeterminate 2 (<1) 1 (<1) 1 (<1) 
 Declined to answer 1 (<1) 0 (<1) 1 (<1) 
 Not applicable 314 (68) 157 (67) 157 (68) 
 Mother disclosed to partner 
    Yes 210 (45) 107 (46) 103 (45) 0.99 
No 60 (13) 31 (13) 29 (12) 
 Not applicable 195 (42) 97 (41) 98 (43) 
 Level of disclosure to partner 
    Full (using the words HIV) 204 (44) 102 (43) 102 (44) 0.213 
Partial (using the words virus) 6 (1) 5 (2) 1 (<1) 
 No disclosure/ not applicable 255 (55) 128 (55) 127 (55) 
 Child's father alive 
    Yes 363 (78) 177 (75) 186 (81) 0.199 
No 94 (20) 52 (22) 42 (18) 
 Don't know 8 (2) 6 (3) 2 (1) 
 Child age median (IQR)in years 7.90 (6.98-8.92) 7.78 (6.86-8.76) 7.97 (7.19-9.05) 0.021 
Child gender 
    Male 232 (50) 131 (56) 101 (44) 0.009 
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Female 233 (50) 104 (44) 129 (56) 
 Table 2: Primary outcome (disclosure) and secondary outcomes of health care engagement, care and custody planning.  
Outcome Total  




 (n = 235) 
 
Enhanced 
standard of care  
 (n = 229) 
 
 
OR [95%CI]  
 
aOR [95%CI]  
PRIMARY OUTCOME      
Disclosed 
   
  
Yes 332 (75) 204 (92) 128 (57) 9.00 [5.14-15.77]  9.88 [5.55-17.57]  
No 113 (25) 17 (8) 96 (43)  
                Missing 19 14 5   
Level of disclosure 
   
 
 Full disclosure 248 (56) 150 (68) 98 (44) 3.67 [2.52-5.35]   4.13 [2.80-6.11]  
Partial disclosure 84 (19) 54 (24) 30 (13)   
No disclosure 113 (25) 17 (8) 96 (43)   
Missing 19 14 5   
SECONDARY OUTCOMES 
   
 
 Took child to clinic visit 
   
 
 Yes 265 (60) 202 (91) 63 (28) 27.17 [15.63-47.24]  31.49 [17.51-56.61]  
No 180 (40) 19 (9) 161 (72)  
 Missing 19 14 5   
Completed care plan for child 
   
 
 Yes 290 (65) 182 (82) 108 (48) 5.01 [3.25-7.74]   5.55 [3.53-8.71]  
No 155 (35) 39 (18) 116 (52)  
 Missing values  19 14 5  
 Discussed care plan with child 
   
 
 Yes 255 (57) 168 (76) 87 (39) 2.90 [1.40-5.98]   3.56 [1.64-7.69]  
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No 35 (8) 14 (6) 21 (9)  
 No care plan completed  155 (35) 39 (18) 116 (52)   
Missing  19 14 5  
 Legal guardian appointed 
   
 
 Yes 382 (86) 200 (90) 182 (81) 2.20 [1.25-3.85]  2.22 [1.25-3.94]   
No 63 (14) 21 (10) 42 (19)  
 Missing values 19 14 5  
 Timing of guardian appointment 
   
 
 3m 223  (50) 139 (63) 84 (38) 0.39 [0.26-0.59]  0.40 [0.26-0.61]   
6m 121 (27) 47 (21) 74 (33)  
 9m 38 (9) 14 (6) 24 (11)  
 No guardian appointed 63 (14) 21 (10) 42 (19)   
Missing  19 14 5  
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Table 3 Secondary outcomes for parent-child relationships, maternal and child mental health, and family functioning  
Outcome 














Mean  (SD) Mean  (SD) Mean  (SD) Mean  (SD) p-value p-value 
MOTHER 
     
 
General Health Subscale (MOS-36) a 63.3 (12.6) 64.1 (11.6) 67.3 (19.8) 66.7 (20.9) 0.357 0.514 
Depression (PHQ-9) 5.6 (5.0) 6.0 (5.7) 4.9 (4.7) 5.0 (4.9) 0.535 0.521 
Anxiety (GAD-7) 4.5 (4.5) 5.0 (5.0) 3.1 (4.0) 3.3 (4.0) 0.334 0.542 
Parenting Stress Total (PSI-36) 86.9 (26.1) 84.9 (24.0) 75.6 (29.5) 77.7 (25.4) 0.312 0.124 
     Parental Distress Subscale 34.7 (12.8) 34.7 (12.5) 27.6 (12.9) 28.4 (11.5) 0.595 0.495 
     Parent-child Relationship Dysfunction Subscale 24.7 (8.8) 22.8 (7.5) 23.1 (10.6) 23.2 (9.5) 0.025 0.044 
     Difficult Child Subscale 27.4 (8.6) 27.5 (8.6) 24.9 (9.8) 26.1 (8.8) 0.946 0.185 
CHILD 
    
  
Child Behaviour Total problems (CBCL) b 52.9 (9.1) 52.0 (8.9) 47.1 (10.5) 47.1 (9.8) 0.319 0.268 
    Internalising  53.7 (9.8) 53.0 (9.5) 47.0 (10.5) 47.3 (9.9) 0.382 0.321 
    Externalising  51.9 (10.8) 51.9 (9.9) 46.4 (11.6) 46.1 (10.8) 0.845 0.754 
FAMILY 
    
  
General Functioning Subscale (FAD) 2.5 (0.3) 2.5 (0.3) 2.4 (0.3) 2.4 (0.3) 0.650 0.242 
a. p-values result from a t-test for difference between 9 months and baseline by arms; 
b. p-values are for main effects of differences between 9 months and baseline by arm adjusting for maternal employment, gender, and age; 
the models included an interaction term between time point and arm (interaction model).  
c. General Health Subscale of the MOS - higher scores = better health related quality of life;  
d. CBCL RTS - test developer norming software produces a standardised t-score by disorder; higher scores = more problem 
e. Analysis based on complete cases at 9 months, using all available data, excluding loss to follow up in intervention (n=22) and enhanced 
standard of care (n=14) 
